Stocktoria
VERACYTE, INC. VCYT
VERACYTE, INC. (VCYT) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $517.1M at a 12.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-29 | Guggenheim | Buy (main) |
| 2026-06-01 | Needham | Buy (main) |
| 2026-05-28 | Needham | Buy (reit) |
| 2026-05-06 | Canaccord Genuity | Hold (main) |
| 2026-05-06 | UBS | Buy (main) |
| 2026-04-20 | Canaccord Genuity | Hold (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.305 |
| Retained earnings / assets | -0.269 |
| EBIT / assets | 0.041 |
| Equity / liabilities | 13.579 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VCYT | VERACYTE, INC. | 7/9 | 15.66 | 61.2 | +16% |
| CDNA | CareDx, Inc. | 4/9 | 0.16 | — | +13.8% |
| CSTL | CASTLE BIOSCIENCES INC | 3/9 | 6.15 | — | +3.7% |
| FLGT | Fulgent Genetics, Inc. | 3/9 | 14.37 | — | +13.8% |
| BLLN | BillionToOne, Inc. | 7/9 | 7.37 | 729.2 | +100% |
| GRAL | GRAIL, Inc. | 4/9 | -2.86 | — | +17.2% |
| BDSX | BIODESIX INC | 3/9 | -19.59 | — | +24.1% |
About VERACYTE, INC.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
FAQ
Is VCYT financially healthy?
VERACYTE, INC.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does VCYT pay a dividend?
No, VERACYTE, INC. does not currently pay a dividend.
How profitable is VCYT?
In FY2025, VERACYTE, INC. had a net margin of 12.8% and a return on equity of 5.1%.
What is VCYT's P/E ratio?
VERACYTE, INC.'s trailing price-to-earnings (P/E) ratio is about 61.2×, based on its latest annual earnings.
What is the analyst price target for VCYT?
The average Wall-Street price target for VERACYTE, INC. is $50.60, about 13.2% above the recent price, from 10 analysts (consensus: buy).
Is VCYT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on VERACYTE, INC.: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 61.2×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.